Introduction

The Mitogen Activated Protein Kinase (MAPK) pathway is one of the most commonly mutated signaling pathways in human cancers. While a range of small molecule inhibitors have been developed to inhibit the upstream and downstream effectors of this pathway, resistance remains a significant challenge.

This conference will focus on both the basic and clinical aspects of the regulation of signaling through the MAPK pathway and its role in cancer. A thorough understanding of the mechanisms of intrinsic and adaptive resistance is crucial for the development of more effective agents. Additionally, as the MAPK pathway can also contribute to cross-resistance to immune checkpoint blockers, alternative combination therapies and potential targets will also be discussed at the conference.

By examining the regulation of the MAPK pathway and its impact on cancer, there is real potential to make progress in improving treatment outcomes.

Register now

Target audience

Those in academia and industry that are interested in the role of the MAPK pathway in the context of genetically targeted and immune-based anticancer therapies. The meeting will have a focus on both the mechanistic aspects of gene regulation, target validation and drug development, and emerging clinical and translational opportunities. 

Topics to be covered

• Regulation of MAPK signaling
• Drug resistance mechanisms
• Rational combination therapies
• Cross-resistance to immune modulators

Scientific Programme Committee

• Rene Bernards, Netherlands
• Marco Hofmann, Austria
• Ralph Neumuller, Austria
• Anna Obenauf, Austria
• Marisol Soengas, Spain

Follow us on twitter for updates @EACRnews and engage with the conference with #eacrMAPKpathway